Medicare has finished negotiating a second group of prescription-drug prices, and the new figures take effect on January 1, 2027. The list covers 15 widely used Part D drugs, including the product group containing Ozempic, Rybelsus and Wegovy. Measured against the 2024 list prices used by the government, the negotiated prices are 38% to 85% lower, making this a finalized program change rather than an estimate about what manufacturers might do.
The 15 negotiated prices Medicare has locked in
The drugs treat diabetes, obesity, cancer, asthma, chronic obstructive pulmonary disease and other serious conditions. They were selected because Medicare Part D spending on the products was high and the medicines met the program’s eligibility rules. About 5.3 million Part D enrollees used the 15 drugs in 2024, according to the federal figures, and gross covered prescription costs for them totaled roughly $42.5 billion.
CMS announced that the new maximum fair prices will generate an estimated 44% reduction in net spending, or about $12 billion, compared with 2024 spending. Its official November 2025 announcement confirms that all 15 negotiated prices become effective in 2027. The percentage range in the headline comes from comparing each price with the 2024 wholesale acquisition cost used in the agency’s public fact sheet.
The Ozempic group illustrates why dosage details matter. CMS negotiated one 30-day-equivalent price across Ozempic, Rybelsus and Wegovy, then published package-specific amounts for different strengths and forms. The negotiated figure is not a promise that every prescription at every pharmacy will carry one identical cash price. It is the statutory price Medicare plans and participating manufacturers must use for covered units under the program.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Why a large list-price cut may not match a copay
The 38% to 85% figures compare negotiated prices with list prices, not with the amount an enrollee paid at the counter in 2026. Part D plans already negotiate rebates and place drugs on tiers, while patients pay deductibles, coinsurance or copayments under their particular plan. A drug can therefore receive a steep maximum-fair-price reduction without producing an equally steep percentage change in every beneficiary’s personal bill.
The CMS negotiated-price fact sheet makes that comparison transparent by publishing the 2024 list-price benchmark, the 2027 maximum fair price and the resulting discount for every product. It also estimates what Medicare would have saved had the prices applied in 2024. Those comparisons measure program-level leverage; an enrollee’s savings will depend on plan design, the drug’s formulary placement and whether the prescription is covered.
The annual Part D out-of-pocket ceiling still matters alongside negotiation. A beneficiary using an expensive selected drug may reach the cap sooner than someone with modest medication costs, after which covered prescriptions cost nothing for the rest of the year. Lower negotiated prices can reduce what Medicare and plans spend and may lower cost sharing before the cap, while the cap limits the beneficiary’s total exposure. The two policies work at different points in the payment chain.
Another distinction is the difference between gross and net spending. A list price is the public starting price before rebates and discounts, while net spending reflects concessions that Medicare plans already receive. CMS says the negotiated group would have reduced net covered prescription-drug costs by about 36% had the prices applied in 2024, even though the individual list-price comparisons span 38% to 85%. Both statements can be true because they use different denominators. The larger percentage range describes product-by-product discounts from published list prices; the smaller aggregate measure compares the program’s negotiated result with spending after existing concessions. For readers judging the scale of the policy, the net measure is closer to the savings experienced by the Medicare program, while plan documents remain the best guide to a particular enrollee’s cost.
The 2027 plan documents will show the household effect
Plan formularies and notices of change will translate the federal prices into practical terms. A selected drug can remain subject to prior authorization, step therapy or a preferred-pharmacy network even after its negotiated price begins. The relevant comparison for a household is the total annual cost under an available plan: premiums plus expected cost sharing, not the negotiated price in isolation.
CMS maintains a current selected-drug and negotiated-price page with the applicable product codes and updates. That record is important because a brand family may contain multiple package sizes and National Drug Codes. It is also the authoritative place to distinguish the 2027 group, whose prices are settled, from the third negotiation cycle for prices that will not take effect until 2028.
The clearest conclusion is narrower than the advertising language surrounding drug prices but still consequential. Medicare has secured substantially lower statutory prices for 15 costly products, those prices begin in 2027, and Ozempic is among them. The exact savings at a pharmacy counter will arrive through each plan’s benefit design, yet the underlying price reduction is already fixed in the federal record. That makes the autumn plan comparison unusually concrete: beneficiaries can examine formulary placement and cost sharing against a government price that is no longer hypothetical, while plans must build coverage around the negotiated amount rather than the earlier list-price benchmark.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
